These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 17112225)

  • 1. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
    Stevens JL
    Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding mechanisms of toxicity: insights from drug discovery research.
    Houck KA; Kavlock RJ
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):163-78. PubMed ID: 18063003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting interactions from mechanistic information: can omic data validate theories?
    Borgert CJ
    Toxicol Appl Pharmacol; 2007 Sep; 223(2):114-20. PubMed ID: 17306318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future needs for developmental toxicity testing.
    Makris SL; Kim JH; Ellis A; Faber W; Harrouk W; Lewis JM; Paule MG; Seed J; Tassinari M; Tyl R
    Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):384-94. PubMed ID: 21922641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of emerging technologies in toxicology and safety assessment.
    Reynolds VL
    Int J Toxicol; 2005; 24(3):135-7. PubMed ID: 16040564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
    Muller PY; Dieterle F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1023-38. PubMed ID: 19611406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of genomics in preclinical drug safety evaluation.
    Lord PG; Nie A; McMillian M
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving structure-linked access to publicly available chemical toxicity information.
    Richard AM; Williams CR; Cariello NF
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):136-43. PubMed ID: 11865667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative test methods in inhalation toxicology: challenges and opportunities.
    Costa DL
    Exp Toxicol Pathol; 2008 Jun; 60(2-3):105-9. PubMed ID: 18486462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assuring safety without animal testing: Unilever's ongoing research programme to deliver novel ways to assure consumer safety.
    Westmoreland C; Carmichael P; Dent M; Fentem J; MacKay C; Maxwell G; Pease C; Reynolds F
    ALTEX; 2010; 27(3):61-5. PubMed ID: 21113564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.